Decoy Therapeutics Inc. (NASDAQ:DCOY) appeared in the 13F filings of 4 institutional investors for the quarter ended June 30, 2026.
Their combined stake equaled 0.81% of outstanding shares in Q2 2026, up from 0.30% in Q1 2026.
Total shares held in Decoy Therapeutics rose 168.30% versus Q1 2026.
Among the 4 holders of Decoy Therapeutics, 2 added to their positions and 2 reduced their stakes.
In total, institutional investors held 4.32K shares of Decoy Therapeutics at the end of Q2 2026, up 2.71K from the prior quarter.
Vanguard Capital Management LLC led 13F holders of DCOY with 4.03K shares as of June 30, 2026, or 0.76% of shares outstanding.
Among holders that kept a stake in Decoy Therapeutics, the biggest sellers in Q2 2026 were Tower Research Capital LLC (-765 shares) and UBS Group AG (-521 shares).
According to Business Quant data, the leading holders of DCOY for Q2 2026 were Vanguard Capital Management LLC (4.03K shares), Tower Research Capital LLC (256 shares), UBS Group AG (25 shares) and Caitong International Asset Management Co., Ltd (2 shares).